These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8048526)

  • 21. Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.
    Brock JH; Licéaga J; Arthur HM; Kontoghiorghes GJ
    Am J Hematol; 1990 May; 34(1):21-5. PubMed ID: 2327400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.
    Chenoufi N; Hubert N; Loréal O; Morel I; Pasdeloup N; Cillard J; Brissot P; Lescoat G
    J Hepatol; 1995 Aug; 23(2):166-73. PubMed ID: 7499788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of iron chelators on placental uptake and transfer of iron in rat.
    Wong CT; McArdle HJ; Morgan EH
    Am J Physiol; 1987 May; 252(5 Pt 1):C477-82. PubMed ID: 3578500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of iron excretion via monoanionic 3-hydroxypyrid-4-ones.
    Molenda JJ; Jones MM; Basinger MA
    J Med Chem; 1994 Jan; 37(1):93-8. PubMed ID: 8289206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biliary iron excretion in normal and iron-loaded rats after desferrioxamine and CaDTPA.
    Figueroa WG; Thompson JH
    Am J Physiol; 1968 Oct; 215(4):807-10. PubMed ID: 5676381
    [No Abstract]   [Full Text] [Related]  

  • 26. PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.
    Wong CS; Kwok JC; Richardson DR
    Biochim Biophys Acta; 2004 Dec; 1739(1):70-80. PubMed ID: 15607119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron mobilization, cytoprotection, and inhibition of cell proliferation in normal and transformed rat hepatocyte cultures by the hydroxypyridinone CP411, compared to CP20: a biological and physicochemical study.
    Gaboriau F; Chantrel-Groussard K; Rakba N; Loyer P; Pasdeloup N; Hider RC; Brissot P; Lescoat G
    Biochem Pharmacol; 2004 Apr; 67(8):1479-87. PubMed ID: 15041465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
    Wongjaikam S; Kumfu S; Khamseekaew J; Sripetchwandee J; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
    PLoS One; 2016; 11(7):e0159414. PubMed ID: 27428732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
    Rai BL; Dekhordi LS; Khodr H; Jin Y; Liu Z; Hider RC
    J Med Chem; 1998 Aug; 41(18):3347-59. PubMed ID: 9719587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
    Emara AM; El Kelany RS; Moustafa KA
    Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A rapid assay for evaluation of iron-chelating agents in rats.
    Pippard MJ; Johnson DK; Finch CA
    Blood; 1981 Oct; 58(4):685-92. PubMed ID: 7272500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.
    Kontoghiorghes GJ
    Mol Pharmacol; 1986 Dec; 30(6):670-3. PubMed ID: 3785144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of the iron-clearing properties of parabactin and desferrioxamine.
    Bergeron R; Streiff RR; King W; Daniels RD; Wiegand J
    Blood; 1993 Oct; 82(8):2552-7. PubMed ID: 8400302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure/activity relationships affecting the ability of monoanionic 3-hydroxyprid-4-ones to mobilize iron.
    Molenda JJ; Jones MM; Cecil KM; Basinger MA
    Chem Res Toxicol; 1994; 7(6):815-22. PubMed ID: 7696537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron chelation therapy.
    Hoffbrand AV; Wonke B
    J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary and biliary excretion of aluminoxamine and ferrioxamine in dogs with various renal function.
    D'Haese PC; Lamberts LV; Verpooten GA; Vaneerdeweg W; Jurgens A; Arakelian S; Babloyan A; Digenis P; Tjalma W; De Broe ME
    Kidney Int; 1994 Jan; 45(1):76-84. PubMed ID: 8127024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transport of lactoferrin from blood to bile in the rat.
    Regoeczi E; Chindemi PA; Hu WL
    Hepatology; 1994 Jun; 19(6):1476-82. PubMed ID: 8188179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biliary excretion of pravastatin and taurocholate in rats with bile salt export pump (Bsep) impairment.
    Cheng Y; Freeden C; Zhang Y; Abraham P; Shen H; Wescott D; Humphreys WG; Gan J; Lai Y
    Biopharm Drug Dispos; 2016 Jul; 37(5):276-86. PubMed ID: 27059119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence for a low Km transporter for non-transferrin-bound iron in isolated rat hepatocytes.
    Barisani D; Berg CL; Wessling-Resnick M; Gollan JL
    Am J Physiol; 1995 Oct; 269(4 Pt 1):G570-6. PubMed ID: 7485509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.